glp 1 agonist classification of GLP-1 RAs based on different parameters [13] Understanding incretin-based therapies made simple
Description
2013;57:e154e159
It was also found that GLP-1 agonist use for T2DM exhibited significantly higher rates of alopecia ( P= 0.000) and hyperhidrosis ( P= 0.000) in comparison to use for weight management
![glp 1 agonist classification of GLP-1 RAs based on different parameters [13] Understanding incretin-based therapies made simple](https://i.ytimg.com/vi/4fx-yLrEa24/maxresdefault.jpg)
Tesamorelin and growth hormone secretagogues Growth hormone secretagogues like tesamorelin, ipamorelin, and CJC-1295 promote growth hormone release, which indirectly supports fat metabolism
![glp 1 agonist classification of GLP-1 RAs based on different parameters [13] Understanding incretin-based therapies made simple](https://www.ijbs.com/ms/getimage.php?name=ijbsv17p2050g002.jpg)
Novo Nordisk Inc
![glp 1 agonist classification of GLP-1 RAs based on different parameters [13] Understanding incretin-based therapies made simple](https://www.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/1004044/fendo-13-1004044-HTML/image_m/fendo-13-1004044-g001.jpg)
1 2 "Ozempic approved in Japan for the treatment of type 2 diabetes" (Press release)
![glp 1 agonist classification of GLP-1 RAs based on different parameters [13] Understanding incretin-based therapies made simple](https://www.researchgate.net/publication/319132415/figure/tbl1/AS:670712683589662@1536921773845/Overview-of-GLP-1-Receptor-Agonists-Available-in-the-United-States-for-the-Treatment-of.png)
Du L, Qin J, Wang D, et al